{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:13:49Z","timestamp":1792098829995,"version":"4.4.0"},"reference-count":204,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.kint.2021.03.020","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T12:20:45Z","timestamp":1617884445000},"page":"1280-1295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":202,"title":["Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference"],"prefix":"10.1016","volume":"99","author":[{"given":"Jodie L.","family":"Babitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele F.","family":"Eisenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker H.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit V.","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine W.","family":"Swinkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Cherng","family":"Tarng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman B.","family":"Dr\u00fceke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Abu-Alfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Barton","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatole","family":"Besarab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine Biddle","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Casadevall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Cases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"de Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Z.","family":"Ginzburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence T.","family":"Goodnough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Hanudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten L.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Minutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeta","family":"Nemeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio T.","family":"Obrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Cheon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pecoits-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatrik M.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce S.","family":"Spinowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kriang","family":"Tungsanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl P.","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Yee-Moon Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.03.020_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.020_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12882-018-0861-1","article-title":"Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States","volume":"19","author":"St Peter","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3346\/jkms.2017.32.2.249","article-title":"The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)","volume":"32","author":"Ryu","year":"2017","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.kint.2021.03.020_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/1744-9987.12712","article-title":"Burden of anemia in chronic kidney disease patients in Japan: a literature review","volume":"22","author":"Akizawa","year":"2018","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.020_bib5","article-title":"Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study","volume":"95","author":"Li","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.kint.2021.03.020_bib6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.4103\/1319-2442.248296","article-title":"Assessment of iron status in predialysis chronic kidney disease patients in a Nigerian Tertiary Hospital","volume":"29","author":"Iyawe","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kint.2021.03.020_bib7","first-page":"39","article-title":"Association of circulatory iron deficiency with an enlarged heart in patients with end-stage kidney disease","volume":"29","author":"Hayashi","year":"2019","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.kint.2021.03.020_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10157-017-1468-8","article-title":"Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease","volume":"22","author":"Sato","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib11","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4103\/1319-2442.248306","article-title":"Impact of correction of anemia in end-stage renal disease patients on cerebral circulation and cognitive functions","volume":"29","author":"Shaker","year":"2018","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kint.2021.03.020_bib12","first-page":"6987240","article-title":"Posttransplant anemia as a prognostic factor of mortality in kidney-transplant recipients","author":"Majernikova","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.kint.2021.03.020_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215920","article-title":"Low-normal hemoglobin levels and anemia are associated with increased risk of end-stage renal disease in general populations: a prospective cohort study","volume":"14","author":"Yi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.020_bib14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/tri.12821","article-title":"Iron deficiency, anemia, and mortality in renal transplant recipients","volume":"29","author":"Eisenga","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2021.03.020_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41581-019-0197-5","article-title":"The multifaceted role of iron in renal health and disease","volume":"16","author":"van Swelm","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib16","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2021.03.020_bib17","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A\u00a0trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib18","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib19","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11845-018-1823-0","article-title":"Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience","volume":"188","author":"Gardiner","year":"2019","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.kint.2021.03.020_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ndt\/gfv298","article-title":"Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013","volume":"31","author":"Evans","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib23","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1681\/ASN.2014090922","article-title":"Considerations and challenges in defining optimal iron utilization in hemodialysis","volume":"26","author":"Charytan","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12882-018-1119-7","article-title":"Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015)","volume":"19","author":"Park","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib25","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2015060673","article-title":"International comparisons to assess effects of payment and regulatory changes in the United States on anemia practice in patients on hemodialysis: The Dialysis Outcomes and Practice Patterns Study","volume":"27","author":"Fuller","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1159\/000370334","article-title":"Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status","volume":"40","author":"Thamer","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2018-06-815894","article-title":"Liver iron sensing and body iron homeostasis","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib28","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib29","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib30","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1073\/pnas.0409808102","article-title":"Regulation of hepcidin transcription by interleukin-1 and interleukin-6","volume":"102","author":"Lee","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.03.020_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib32","first-page":"108","article-title":"Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker","volume":"73","author":"van der Weerd","year":"2015","journal-title":"Neth J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib33","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1681\/ASN.V7122654","article-title":"The evaluation of iron status in hemodialysis patients","volume":"7","author":"Fishbane","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0272-6386(95)90649-5","article-title":"Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era","volume":"26","author":"Kalantar-Zadeh","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib35","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","article-title":"The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin","volume":"16","author":"Tessitore","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2215\/CJN.04280609","article-title":"Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?","volume":"5","author":"Stancu","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib38","author":"Besarab"},{"key":"10.1016\/j.kint.2021.03.020_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.294.8.924","article-title":"Screening healthy infants for iron deficiency using reticulocyte hemoglobin content","volume":"294","author":"Ullrich","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2021.03.020_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/00365513.2019.1622149","article-title":"Assessment of iron-restricted erythropoiesis in chronic renal disease: evaluation of Abbott CELL-DYN Sapphire mean reticulocyte hemoglobin content (MCHr)","volume":"79","author":"Urrechaga","year":"2019","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.kint.2021.03.020_bib41","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cll.2014.10.004","article-title":"Clinical utility of reticulocyte parameters","volume":"35","author":"Piva","year":"2015","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.kint.2021.03.020_bib43","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1046\/j.1523-1755.2001.00077.x","article-title":"A\u00a0randomized trial of iron deficiency testing strategies in hemodialysis patients","volume":"60","author":"Fishbane","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0272-6386(97)90104-9","article-title":"Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO","volume":"30","author":"Mittman","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib45","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V83.10.3100.3100","article-title":"Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy","volume":"83","author":"Brugnara","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MOH.0b013e32835f5933","article-title":"Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium","volume":"20","author":"Brugnara","year":"2013","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.kint.2021.03.020_bib47","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/ndt\/gft338","article-title":"Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics","volume":"28","author":"Minutolo","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2021.03.020_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfz192","article-title":"Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease","volume":"36","author":"Awan","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/nep.12493","article-title":"Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study","volume":"20","author":"Iimori","year":"2015","journal-title":"Nephrology"},{"key":"10.1016\/j.kint.2021.03.020_bib51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2215\/CJN.01670408","article-title":"Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004","volume":"4","author":"Fishbane","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/kisup.2015.6","article-title":"Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry","volume":"5","author":"Hamano","year":"2015","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2021.03.020_bib55","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3747\/pdi.2018.00249","article-title":"International anemia prevalence and management in peritoneal dialysis patients","volume":"39","author":"Perlman","year":"2019","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.kint.2021.03.020_bib56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1681\/ASN.2012050433","article-title":"Management of anemia in children receiving chronic peritoneal dialysis","volume":"24","author":"Borzych-Duzalka","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib57","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ehf2.12333","article-title":"Iron deficiency in chronic heart failure: case-based practical guidance","volume":"5","author":"Lam","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.kint.2021.03.020_bib58","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib59","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2019.04.029","article-title":"An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic veterans with predialysis chronic kidney disease","volume":"96","author":"Cho","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib60","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib61","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2021.03.020_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.ajkd.2015.09.011","article-title":"Comparative effectiveness of iron and erythropoiesis-stimulating agent dosing on health-related quality of life in patients receiving hemodialysis","volume":"67","author":"Freburger","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib65","first-page":"CD007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"2","author":"O'Lone","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2021.03.020_bib66","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.03.020_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2021.03.020_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019240","article-title":"Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials","volume":"8","author":"Houston","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.kint.2021.03.020_bib69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejim.2019.02.009","article-title":"Iron supplementation for restless legs syndrome\u2014a systematic review and meta-analysis","volume":"63","author":"Avni","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.kint.2021.03.020_bib70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood-2017-03-772715","article-title":"Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron","volume":"130","author":"Stefanova","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00253-18","article-title":"Hepcidin protects against lethal Escherichia coli sepsis in mice inoculated with isolates from septic patients","volume":"86","author":"Stefanova","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.kint.2021.03.020_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(06)67962-2","article-title":"Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial","volume":"367","author":"Sazawal","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2021.03.020_bib73","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0378-4274(95)03532-X","article-title":"Toxicity of iron and hydrogen peroxide: the Fenton reaction","volume":"82\u201383","author":"Winterbourn","year":"1995","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.kint.2021.03.020_bib74","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/1744-9987.13458","article-title":"Labile plasma iron levels in chronic hemodialysis patients treated by intravenous iron supplementation","volume":"24","author":"Bnaya","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.020_bib75","doi-asserted-by":"crossref","first-page":"F871","DOI":"10.1152\/ajprenal.00388.2016","article-title":"Catalytic iron and acute kidney injury","volume":"311","author":"Leaf","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.020_bib76","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3324\/haematol.2015.133983","article-title":"Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders","volume":"101","author":"de Swart","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2021.03.020_bib77","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00063-009-1192-6","article-title":"Hereditary hemochromatosis","volume":"104","author":"Niederau","year":"2009","journal-title":"Med Klin"},{"key":"10.1016\/j.kint.2021.03.020_bib78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A\u00a0randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib79","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/ndt\/gfw264","article-title":"Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial","volume":"32","author":"Roger","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib80","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of intravenous iron in dialysis: a systematic review and meta-analysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib81","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1681\/ASN.2019090972","article-title":"Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial","volume":"31","author":"Macdougall","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib82","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with nondialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib83","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/dmrr.2394","article-title":"Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence","volume":"29","author":"Kunutsor","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.kint.2021.03.020_bib84","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"Wang","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2021.03.020_bib85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2215\/CJN.00930118","article-title":"Rest easy with intravenous iron for dialysis patients? High dose IV iron safety","volume":"13","author":"Li","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib86","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2215\/CJN.03970318","article-title":"Safety of dynamic intravenous iron administration strategies in hemodialysis patients","volume":"14","author":"Li","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib87","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1681\/ASN.2012121164","article-title":"Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients","volume":"24","author":"Brookhart","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41581-019-0189-5","article-title":"FGF23 at the crossroads of phosphate, iron economy and erythropoiesis","volume":"16","author":"Edmonston","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib89","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2021.03.020_bib90","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.kint.2021.03.020_bib91","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2021.03.020_bib92","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.kint.2021.03.020_bib93","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.kint.2021.03.020_bib94","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ndt\/gfy189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib95","article-title":"Epoetin beta and C-terminal fibroblast growth factor 23 in patients with chronic heart failure and chronic kidney disease","volume":"8","author":"Eisenga","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.kint.2021.03.020_bib96","doi-asserted-by":"crossref","first-page":"F132","DOI":"10.1152\/ajprenal.00081.2017","article-title":"Acute blood loss stimulates fibroblast growth factor 23 production","volume":"314","author":"Rabadi","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.020_bib97","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3324\/haematol.2017.167882","article-title":"Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow","volume":"102","author":"Clinkenbeard","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2021.03.020_bib98","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.kint.2021.03.020_bib99","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.kint.2019.07.026","article-title":"Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease","volume":"96","author":"Francis","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib100","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2018101016","article-title":"A\u00a0pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD","volume":"30","author":"Block","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib101","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib102","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2021.03.020_bib103","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.020_bib104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.kint.2018.02.017","article-title":"The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk","volume":"94","author":"Pastor-Arroyo","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphys.2019.00304","article-title":"The EPO-FGF23 signaling pathway in erythroid progenitor cells: opening a new area of research","volume":"10","author":"van Vuren","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.kint.2021.03.020_bib106","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"FASEB J"},{"key":"10.1016\/j.kint.2021.03.020_bib107","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s11914-018-0492-2","article-title":"Non-renal-related mechanisms of FGF23 pathophysiology","volume":"16","author":"Hanudel","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.kint.2021.03.020_bib108","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/ijms20174195","article-title":"The role of fibroblast growth factor 23 in inflammation and anemia","volume":"20","author":"Czaya","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"Suppl 1","key":"10.1016\/j.kint.2021.03.020_bib109","first-page":"S28","article-title":"Oral iron supplementation: potential implications for the gut microbiome and metabolome in patients with CKD","volume":"21","author":"Kortman","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.kint.2021.03.020_bib110","first-page":"2154S","article-title":"Landscape analysis of interactions between nutrition and vaccine responses in children","volume":"139","author":"Savy","year":"2009","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.kint.2021.03.020_bib111","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3389\/fimmu.2020.01313","article-title":"Iron deficiency anemia at time of vaccination predicts decreased vaccine response and iron supplementation at time of vaccination increases humoral vaccine response: a birth cohort study and a randomized trial follow-up study in Kenyan infants","volume":"11","author":"Stoffel","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2021.03.020_bib112","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-019-11002-5","article-title":"Iron-dependent histone 3 lysine 9 demethylation controls B cell proliferation and humoral immune responses","volume":"10","author":"Jiang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.03.020_bib113","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib114","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2215\/CJN.00080116","article-title":"Iron therapy challenges for the treatment of nondialysis CKD patients","volume":"11","author":"Locatelli","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2016.04.018","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis","volume":"68","author":"Shepshelovich","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib116","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib117","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(17)30182-5","article-title":"Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials","volume":"4","author":"Stoffel","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2021.03.020_bib118","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.kint.2021.03.020_bib119","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","article-title":"Modern iron replacement therapy: clinical and pathophysiological insights","volume":"107","author":"Girelli","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.kint.2021.03.020_bib120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2021.03.020_bib121","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2215\/CJN.05320513","article-title":"A\u00a0randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD","volume":"9","author":"Macdougall","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron isomaltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.kint.2021.03.020_bib123","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1185\/03007995.2012.760444","article-title":"Comparison of adverse event profile of intravenous iron sucrose and iron sucrose similar in postpartum and gynecologic operative patients","volume":"29","author":"Lee","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.kint.2021.03.020_bib124","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1093\/ndt\/gfr024","article-title":"Do two intravenous iron sucrose preparations have the same efficacy?","volume":"26","author":"Rottembourg","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135967","article-title":"Efficiency of original versus generic intravenous iron formulations in patients on haemodialysis","volume":"10","author":"Aguera","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.020_bib126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2369-14-167","article-title":"Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study","volume":"14","author":"Prats","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib127","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2021.03.020_bib128","first-page":"1628","article-title":"A\u00a0controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy","volume":"33","author":"Huang","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2215\/CJN.06020710","article-title":"Proteinuria induced by parenteral iron in chronic kidney disease\u2014a comparative randomized controlled trial","volume":"6","author":"Agarwal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12882-017-0444-6","article-title":"Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial","volume":"18","author":"Macdougall","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib131","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00467-018-4014-3","article-title":"Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis","volume":"33","author":"Pratt","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib132","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jcph.819","article-title":"Pharmacokinetics of ferric pyrophosphate citrate, a novel iron salt, administered intravenously to healthy volunteers","volume":"57","author":"Pratt","year":"2017","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.kint.2021.03.020_bib133","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10534-018-0142-2","article-title":"Ferric pyrophosphate citrate: interactions with transferrin","volume":"31","author":"Pratt","year":"2018","journal-title":"Biometals"},{"key":"10.1016\/j.kint.2021.03.020_bib134","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","article-title":"Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients","volume":"30","author":"Fishbane","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib135","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ki.2015.203","article-title":"Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients","volume":"88","author":"Gupta","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib136","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib137","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12882-018-1196-7","article-title":"Achievement of renal anemia KDIGO targets by two different clinical strategies\u2014a European hemodialysis multicenter analysis","volume":"20","author":"Drozdz","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib138","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1093\/ndt\/gfy190","article-title":"Association between serum ferritin and mortality: findings from the USA, Japan and European Dialysis Outcomes and Practice Patterns Study","volume":"33","author":"Karaboyas","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib139","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.2215\/CJN.00710111","article-title":"C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients","volume":"6","author":"Bazeley","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib140","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.2019004653","article-title":"A\u00a0fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease","volume":"136","author":"Petzer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib141","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A\u00a0systematic analysis of global anemia burden from 1990 to 2010","volume":"123","author":"Kassebaum","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2021.03.020_bib142","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3390\/nu11102424","article-title":"Anemia of inflammation with an emphasis on chronic kidney disease","volume":"11","author":"Begum","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.kint.2021.03.020_bib143","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"10.1016\/j.kint.2021.03.020_bib144","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal anemia: current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib146","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","article-title":"Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease","volume":"92","author":"Sugahara","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib147","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib148","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib149","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.03.020_bib150","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib151","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib152","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a Phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib153","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled Phase 2b trial followed by long-term trial","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.03.020_bib154","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib155","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to Stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.kint.2021.03.020_bib157","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.020_bib158","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000351175","article-title":"Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease","volume":"37","author":"McCullough","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib159","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/gfn601","article-title":"Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease","volume":"24","author":"Vaziri","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib160","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, Phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib161","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib162","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A\u00a024-week anemia correction study of daprodustat in Japanese dialysis patients","volume":"24","author":"Tsubakihara","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.020_bib163","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, Phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.020_bib164","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.020_bib165","author":"Provenzano"},{"key":"10.1016\/j.kint.2021.03.020_bib166","author":"Nangaku"},{"key":"10.1016\/j.kint.2021.03.020_bib167","doi-asserted-by":"crossref","unstructured":"Nangaku M, Kondo K, Ueta K, et\u00a0al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study [e-pub ahead of print]. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab055. Accessed April 18, 2021.","DOI":"10.1093\/ndt\/gfab055"},{"key":"10.1016\/j.kint.2021.03.020_bib168","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000513103","article-title":"Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52week randomized open-label Phase 3 trial","volume":"52","author":"Nangaku","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib169","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.020_bib170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A\u00a0phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.03.020_bib171","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Intl Rep"},{"key":"10.1016\/j.kint.2021.03.020_bib172","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized Phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib173","doi-asserted-by":"crossref","unstructured":"Shutov E, Sulowicz W, Esposito C. Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS) [e-pub ahead of print]. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfab057. Accessed April 18, 2021.","DOI":"10.1093\/ndt\/gfab057"},{"key":"10.1016\/j.kint.2021.03.020_bib174","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007875","article-title":"Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors","volume":"4","author":"Volke","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.020_bib175","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.020_bib176","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2021.03.020_bib177","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib178","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib179","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.03.020_bib180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2021.03.020_bib181","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2021.03.020_bib182","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1471-4914(01)02090-1","article-title":"Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology","volume":"7","author":"Semenza","year":"2001","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.kint.2021.03.020_bib183","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/BJ20111377","article-title":"Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia","volume":"441","author":"Shen","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.kint.2021.03.020_bib184","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","article-title":"Hypoxia-inducible factor 1alpha activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver","volume":"292","author":"Hwang","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.020_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.020_bib186","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrd4422","article-title":"Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases","volume":"13","author":"Eltzschig","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2021.03.020_bib187","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI84433","article-title":"Hypoxia-dependent regulation of inflammatory pathways in immune cells","volume":"126","author":"Taylor","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.020_bib188","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Schodel","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib189","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.020_bib190","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00439-011-1109-3","article-title":"Genetic determinants of Tibetan high-altitude adaptation","volume":"131","author":"Simonson","year":"2012","journal-title":"Hum Genet"},{"key":"10.1016\/j.kint.2021.03.020_bib191","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1038\/ncomms7863","article-title":"Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension","volume":"6","author":"Newman","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.03.020_bib192","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/MCB.01055-15","article-title":"The endothelial prolyl-4-hydroxylase domain 2\/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice","volume":"36","author":"Kapitsinou","year":"2016","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.kint.2021.03.020_bib193","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1073\/pnas.1602978113","article-title":"HIF2alpha-arginase axis is essential for the development of pulmonary hypertension","volume":"113","author":"Cowburn","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.03.020_bib194","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol"},{"key":"10.1016\/j.kint.2021.03.020_bib195","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib196","first-page":"5071","article-title":"Effects of HIF-1alpha on diabetic retinopathy angiogenesis and VEGF expression","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.kint.2021.03.020_bib197","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.kint.2016.05.020","article-title":"Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification","volume":"90","author":"Mokas","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib198","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1039\/C7SC02103H","article-title":"Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials","volume":"8","author":"Yeh","year":"2017","journal-title":"Chem Sci"},{"key":"10.1016\/j.kint.2021.03.020_bib199","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman Disease","volume":"21","author":"Casper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.kint.2021.03.020_bib200","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.kint.2016.02.006","article-title":"Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications\u2014or even more?","volume":"89","author":"Massy","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.020_bib201","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrd.2016.248","article-title":"Targeting iron metabolism in drug discovery and delivery","volume":"16","author":"Crielaard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.kint.2021.03.020_bib202","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MNH.0000000000000433","article-title":"Activin receptor ligand traps in chronic kidney disease","volume":"27","author":"Jelkmann","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.kint.2021.03.020_bib203","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00467-018-3999-y","article-title":"Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients","volume":"33","author":"Hanudel","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00467-017-3849-3","article-title":"HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics","volume":"34","author":"Kular","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2021.03.020_bib205","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrrheum.2012.36","article-title":"Hypoxia-driven pathways in bone development, regeneration and disease","volume":"8","author":"Maes","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2021.03.020_bib206","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-0874-3","article-title":"HIF-1alpha metabolically controls collagen synthesis and modification in chondrocytes","volume":"565","author":"Stegen","year":"2019","journal-title":"Nature"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253821003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:00:38Z","timestamp":1758762038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253821003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":204,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0085253821003550"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.020","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}